The Institute of Cancer Research’s Annual Report and Financial Statements for the financial year ended 31 July 2025 are available to download below. The document includes the Report of the Board of ...

We provided the first conclusive evidence that the basic cause of cancer is damage to DNA. The discovery changed scientific opinion dramatically and marked a turning point for cancer research. Until ...

Monday 21 to Tuesday 22 September 2026. An opportunity to broaden your understanding of the capabilities and potential of MRI guidance in radiotherapy planning and treatment verification. We invite ...

Our leadership team Professor Kristian Helin Chief Executive and President The Chief Executive is responsible to the Board of Trustees for the overall direction of the ICR’s management, research and ...

We were the first in Europe to develop chemotherapeutic agents, and we discovered, and with The Royal Marsden NHS Foundation Trust developed, the chemotherapy drugs busulfan, chlorambucil, melphalan ...

New research presents clear guidelines on how patient-reported outcomes (PROs) can be used more effectively in early-stage cancer drug trials, helping ensure that patient experiences meaningfully ...

We identified the breast cancer gene BRCA2, which enabled families with a history of breast cancer to be assessed for future risk, and laid the groundwork for developing novel forms of therapy for ...

‘Be part of it’, our strategic plan to engage with our local communities, inspire future diversity in science, and continue to create an environment where public engagement can thrive. The strategy ...

We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

The ICR is one of the world's most influential cancer research organisations – and we are world leaders in identifying cancer genes, discovering cancer drugs and developing precision radiotherapy. By ...

The ICR-CTSU manages a number of trials in different disease sites. View the trials below, ordered by enrolment status.

The fully equipped Baculovirus Facility provides a means of expressing proteins and protein complexes using a Baculovirus / insect cell system (BICS). It supplies the Division of Structural Biology ...